Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy
· Delayed Price · Currency is EUR | Market Cap | 9.91B |
| Revenue (ttm) | 2.55B |
| Net Income (ttm) | 404.39M |
| Shares Out | 204.57M |
| EPS (ttm) | 1.93 |
| PE Ratio | 25.04 |
| Forward PE | 19.64 |
| Dividend | 1.30 (2.69%) |
| Ex-Dividend Date | Nov 24, 2025 |
| Volume | 373,521 |
| Average Volume | 345,005 |
| Open | 48.42 |
| Previous Close | 48.30 |
| Day's Range | 48.28 - 48.82 |
| 52-Week Range | 43.98 - 55.35 |
| Beta | 0.61 |
| RSI | 54.87 |
| Earnings Date | Feb 17, 2026 |
About BIT:REC
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due ... [Read more]
Financial Performance
In 2024, BIT:REC's revenue was 2.34 billion, an increase of 12.45% compared to the previous year's 2.08 billion. Earnings were 416.51 million, an increase of 7.01%.
Financial StatementsNews
Amarin Corp Q4 2025 Earnings Call Transcript
Amarin Corp (NASDAQ: AMRN) held its fourth-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive f...
Recordati reports FY2025 results
Recordati press release (RCDTF): FY 2025 Revenue of €2.62B (+12.0% Y/Y). Net income of €443.6M.
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q4 2025 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q4 2025 Earnings Call Transcript
Moderna, Inc.: Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition t...
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to c...
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Presents at 44th Annual J.P.
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Presents at 44th Annual J.P.
Recordati Launches Isturisa In Canada For Cushing's Disease
(RTTNews) - Recordati Rare Diseases Canada, a unit of Recordati (REC.MI) on Tuesday announced that Isturisa, for the treatment of Cushing's disease, is now available in Canada. The launch follows the ...
Recordati SpA (RICFY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
Recordati SpA (RICFY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q3 2025 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RICFY) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Eugenia Litz - VP & Head of Investor Relations Robert Koremans ...
Amarin targets $70M cost savings and accelerates VAZKEPA European expansion through Recordati partnership
Italy's Recordati CEO sees rare disease drugs exempt from U.S. tariffs
The head of Italian group Recordati expects treatments for rare diseases to be exempted from the 15% tariff the United States plans to impose on imported European pharmaceutical products, he said on W...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA
Amarin Corporation (NASDAQ: AMRN) shares are trading higher Tuesday after the company announced a long-term exclusive license and supply agreement with Recordati S.p.A. to commercialize its cardiovas...
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges
Amarin Corporation Plc (NASDAQ: AMRN) on Tuesday entered into an exclusive long-term license and supply agreement with Recordati S.p.A. , Italy, to commercialize Vazkepa (icosapent ethyl) in 59 count...
Amarin inks licensing deal with Recordati for lead drug Vazkepa
Recordati reports Q1 results
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
Milan, 8 th May 2025 – The Board of Directors of Recordati S.p.A. approved the Group's Interim Report as of 31st March 2025, representing additional voluntary financial reporting(7). The Report was pr...
There is still such a huge need to do better with rare diseases: Recordati CEO
Recordati CEO Rob Koremans joined "Squawk Box Europe" after the pharmaceutical company raised its 2025 revenue and core profit forecasts by more than expected, seeing strong demand for its rare diseas...
Angelini Pharma Said to Discuss Combination With CVC’s Recordati
Italian drugmaker Angelini Pharma SpA is in talks on a potential combination with domestic peer Recordati SpA, which is owned by private equity firm CVC Capital Partners Plc, according to people famil...
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2024 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RCDTF) Q3 2024 Earnings Conference Call November 8, 2024 10:00 AM ET Company Participants Eugenia Litz - VP & Head, Investor Relations Robert K...